DNAprint Genomics (DNAG)

[frogdreaming]

I am also amused by the DNAP-centric viewpoint that DNAP is driving this deal.

People, this is a Biofrontera deal from the get go.

Frudakis didn't start talking about the future as a drug company until Gabriel came on board. Gabriel and Tambori appeared, apparently out of nowhere, but actually as Biofrontera investors on a mission.

Immediately after their arrival they become major shareholders in DNAP based on their willingness to sacrifice salary for stock. The existing company structure is turned on it's head, most of the scientists are ejected, and the new world order takes over.

After enough time has passed to conceal the obvious nature of the plan, lo and behold the 'drug company' that has been hinted at for months ends up being Biofrontera...what a coincidence.

Has it totally escaped your notice, that nowhere in any of the PR's or documentation, from either company, does it ever mention DNAP will have"CONTROL" of Biofrontera. No, it never does! They only ever talk about a Major equity position and gaining 'access' to the drug pipeline, never operational control.

DNAP has agreed to purchase 68% of the Preffered Class B shares. Now if you are paying attention you will be able to deduce that IF 68% of the class B shares is worth 51.7% of the equity in the company, THEN there are obviously other classes of stock in play. Worktoplay has already shown you the differences that exist in the voting characteristics of the various classes of stock. Put 2 and 2 together and see what you get.

For those who can't do such complicated math, the calculation suggests that there is NO direct connection between owning 51.7% of the 'equity' and owning 51.7% of the voting rights. Given that the 'Control' word has never been mentioned, it is a safe bet that DNAP will NOT have voting control over Biofrontera.

I defy anyone to produce evidence to the contrary.

regards,
frog